Procaine treatments for cognition and dementia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Szatmári, Szabolcs ^a   Bereczki, Dániel ^b  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GERIOPTIL; HEMATOPORPHYRIN PLUS PROCAINE; KH3; NOOTROPIC AGENT; PLACEBO; PROCAINE; UNCLASSIFIED DRUG;

ATTENTION; BEHAVIOR; CLINICAL TRIAL; COGNITION; DEMENTIA; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INTELLIGENCE; LEARNING; META ANALYSIS; MIGRAINE; ORIENTATION; RECALL; RECOGNITION; RESTLESSNESS; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL MEMORY;

EID: 55049085022     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005993.pub2     Document Type: Review

References (36)

1. Balaceanu 1989 {published data only} * Balaceanu Stolnici C, Manoiu A, Vrabiescu M. Gerovital h3 effects upon human cognitive behaviour and psychomotor capacity. Romanian Journal of Gerontology and Geriatrics 1989;10(4):277-84.
2. Cashman 1961 {published data only} * Cashman MD, Lawes TGG. A controlled trial of "Gerioptil". BMJ 1961;1(5225):554-6.
3. Hall 1983 {published and unpublished data} * Hall MR, Briggs RS, MacLennan WJ, Marcer D, Robinson MJ, Everett FM. The effects of procaine/haematoporphyrin on age-related decline: a double-blind trial. Age and Ageing 1983;12(4):302-8.
4. Southampton 1982 {unpublished data only} * The Southampton Ageing Project. The Southampton Ageing Project: A trial of KH3. The Southampton Ageing Project 1982.
5. Abrams 1965 {published data only} * Abrams A, Tobin S, Gordon P, Pechtel C, Hilkevitch A. The effects of a European procaine preparation in an aged population. Journal of Gerontology 1965;20(2):139-43.
6. Aslan 1980 {published data only} * Aslan A. A new method for prophylaxis and treatment of aging with novocain-eutrophic and rejuvenating effects. Therapiewoche 1956;7:14-22.
7. Aslan A, Vrabiescu A, Dobre M. Aslavital for children in mentally deficient subjects. Romanian Journal of Gerontology and Geriatrics 1980;1(2):189-94.
8. Aslan A, Vrabiescu A, Dobre M, Polovrageanu E. The aslavital treatment in the recovery of mentally-deficient children. Romanian Journal of Gerontology and Geriatrics 1980;1(1):93-8.
9. Berryman 1961 {published data only} Berryman JAW, Forbes HAW, Simpson-White R. Trial of procaine in old age and chronic degenerative disorders. BMJ 1961;2(5268):1683-4.
10. Czerwenka 1970 {published data only} Czerwenka H, Maly J, Quatember R, Tschabitscher H. Clinical and psychological investigations with a geriatric substance (in German) [Klinische und testpsychologische Untersuchungen mit einem Geriatricum]. Wiener Medizinische Wochenschrift 1970;120(13):217-24.
11. Fee 1961 {published data only} Fee SR, Clark ANG. Trial of procaine in the aged. BMJ 1961;2 (5268):1680-2.
12. Gericke 1961 {published data only} Gericke OL, Lobbv LG, Pardoll DH. An evaluation of procaine in geriatric patients in a mental hospital. Journal of Clinical and Experimental Psychopathology 1961;22:18-33.
13. Hirsch 1961 {published data only} Hirsch J. A clinical trial of procaine hydrochloride. BMJ 1961;2(5268):1684-5.
14. Isaacs 1962 {published data only} Isaacs B. Trials of procaine in aged patients. BMJ 1962;2(5272):188-9.
15. Kant 1962 {published data only} Kant S, Sterne DM. Evaluation of chronically ill patients treated for one year with procaine. Journal of the American Geriatrics Society 1962;10:408-12.
16. Kent 1982 {published data only} * Kent S. The procaine "youth" drugs. Geriatrics 1982;37(4):32-6.
17. Long 1964 {published data only} * Long RF, Gislason SS. The effect of procaine on orientation, attention, memory and weight of aged psychiatric patients. Journal of Neuropsychiatry 1964;5:186-96.
18. May 1962 {published data only} * May RH, Ruland MB, Bylenga ND, Peppel HH. Prolonged procaine therapy in geriatric psychiatric patients. Geriatrics 1962;17:161-8.
19. Olsen 1978 {published data only} * Olsen EJ, Bank L, Jarvik LF. Gerovital-H3: a clinical trial as an antidepressant. Journal of Gerontology 1978;33(4):514-20.
20. Ostfeld 1977 {published data only} * Ostfeld A, Smith CM, Stotsky BA. The systemic use of procaine in the treatment of the elderly: a review. Journal of the American Geriatrics Society 1977;5(1):1- 19.
21. Quatember 1980 {published data only} * Quatember R, Maly J. Neuropsychological methods of examination of age-specific performance parameters [Neuropsychologische Untersuchungsmethoden alterssezifischer Leistungsparameter]. Wiener Medizinische Wochenschrift 1980;130(21):688-92.
22. Rusu 1996 {published data only} * Rusu C, Borsa C, Gradinaru D, Ionescu C, Babeanu S. Antioxidant and lipid-lowering effects of the original procaine-based products. Romanian Journal of Gerontology and Geriatrics 1996;18(3-4):47-61.
23. Sakalis 1974 {published data only} * Sakalis G, Oh D, Gershon S, Shopsin B. A trial of gerovital H-3 in depression during senility. Current Therapeutic Research, Clinical and Experimental 1974;16(1):59-63.
24. Smigel 1960 {published data only} * Smigel JO, Piller J, Murphy C, Lowe C, Gibson J. H-3 (procaine hydrochloride) therapy in aging institutionalized patients: an interim report. Journal of the American Geriatrics Society 1960;8:785-94.
25. Valtonen 1992 {published data only} Valtonen EJ. Procaine chloride as a universal remedy for somatic and psychic symptoms. Suomen Lookorilehti 1992;47(28):1608-11.
26. Zdichynec 1977 {published data only} * Zdichynec B. Successes in novocain therapy in the control of premature ageing [Kurzmitteilung zur Novokaintherapie-Vorbeugung des vorzeitigen Alterns mittels der Novokaintherapie]. Z Alternsforsch 1977;32(3):267-9.
27. Zwerling 1975 {published data only} * Zwerling I, Plutchik R, Hotz M, Kling R, Rubin L, Grossman J, et al.Effects of a procaine preparation (Gerovital H3) in hospitalized geriatric patients: a double-blind study. Journal of the American Geriatrics Society 1975;23(8):355- 9.
28. APA 1987 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
29. DSM IV 1994 American Psychiartric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. Vol IV. IV. Washington, DC, USA: American Psychiatric Publishing, 1994.
30. FDA 1982 Automatic detention alert for Gerovital. http://www.fda.gov/ora/fiars/ora_import_ia6101.html.
31. GH3 2008 http://www.gh3.co.uk/.
32. Higgins 2008 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
33. McKhann 1984 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;4:939-44.
34. Román 1993 Román CG, Tatemichi TK, Erkinjuntti T, et al.Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
35. Ultimate 9 2008 Development of Ultimate 9. http://www. achilleshealthmart.com/vitacel_koch.htm.
36. WHO 1992 World Health Organisation. International classification of diseases, 10th revision. Geneva: World Health Organisation, 1992.